Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to establish the objective response rate (complete
response + partial response) following treatment with VELCADE in combination with cisplatin
plus gemcitabine in patients with locally advanced (Stage IIIb) or metastatic (stage IV
non-small cell lung cancer (NSCLC) who have not received prior antineoplastic therapy for
advanced disease